【24h】

Saliva Biomarker Detection using an Aptamer-based Nanosensor

机译:唾液生物标志物检测使用基于Aptamer的纳米传感器

获取原文

摘要

Aptamers, with numerous advantages over antibodies, such as high stability, resistance to denaturation and degradation, and easy modification possibilities, have found widespread uses in biosensing, drug delivery, disease diagnosis and therapy. The specific binding ability of aptamers to cancer-related markers and cancer cells ensured high performance for early diagnosis of cancer. Carcinoembryonic antigen (CEA) usually is present only at very low levels in the blood of healthy adults, however, the levels can raise in certain kinds of cancers such as colon and rectal cancer, pancreas, breast, ovary or lung cancer, allowing CEA to be used as a tumor marker in clinical tests. Several research groups have further demonstrated the levels of CEA are significantly higher in saliva than in blood/serum. Here, we present an aptamer-based biosensor for CEA's detection with a sensitivity of 0.399 μA/(ng/mL) in saliva. The binding affinities of the selected aptamers to CEA have been evaluated by Surface Plasmon Resonance imaging (SPRi) technology which is a very sensitive method to measure binding interactions of various biomolecules, including proteins, nucleic acids, and phospholipids. Furthermore, instead of using the time-consuming Systematic Evolution of Ligands by Exponential enrichment (SELEX) process, we proposed a molecular dynamics (MD) simulation method to automatically and effectively select target-specific aptamers. It systematically investigates the atomistic details of the binding mechanisms between aptamer and target. Complemented with experimental tests, SPRi validation and MD simulation, this electrochemical aptamer-based biosensing system demonstrates great sensitivity, clinically accuracy and reliability in realizing noninvasive disease detection and monitoring through saliva analysis.
机译:适体,具有众多优于抗体的优势,例如高稳定性,抗变性和降解,并且易于改性可能性,发现了在生物传感,药物递送,疾病诊断和治疗中的广泛应用。适体对癌症相关标志物和癌细胞的特异性结合能力确保了对癌症的早期诊断的高性能。癌症胚抗原(CEA)通常仅存在于健康成人的血液中的非常低的水平,然而,水平可以在某些类型的癌症中提高,如结肠癌和直肠癌,胰腺,乳腺,卵巢或肺癌,允许CEA用作临床试验中的肿瘤标志物。几个研究组进一步证明了唾液中CEA的水平显着高于血液/血清。在这里,我们提出了一种基于Aptamer的生物传感器,用于CEA检测,唾液中的灵敏度为0.399μA/(Ng / ml)。通过表面等离子体共振成像(SPRI)技术评估所选适体与CEA的结合亲和力,这是一种非常敏感的方法,用于测量各种生物分子的结合相互作用,包括蛋白质,核酸和磷脂。此外,不是通过指数富集(SELEX)过程的耗时的配体系统演进,而是提出了一种分子动力学(MD)模拟方法,自动且有效地选择特定于目标的适体。它系统地研究适体和靶标的结合机制的原子细节。补充有实验测试,SPRI验证和MD仿真,这种基于电化学适体的生物传感系统在实现了通过唾液分析来实现了极大的敏感性,临床准确性和可靠性,实现了非侵入性疾病检测和监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号